- Business Wire•10 hours ago
CEL-SCI Corporation today announced that Dr. Daniel Zimmerman, its Senior V.P of Research, Cellular Immunology, presented data with a LEAPS Rheumatoid Arthritis therapeutic vaccine at Madridge‘s International Conference on Vaccines held in Baltimore, MD on February 20-22, 2017.
- Business Wire•4 days ago
CEL-SCI Corporation today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $1.0 million in a registered direct offering.
- Associated Press•12 days ago
On a per-share basis, the Vienna, Virginia-based company said it had net income of 1 cent. The cancer immunotherapy company posted revenue of $7,300 in the period. Its adjusted revenue was $7,000. In the ...
CVM : Summary for Cel-Sci Corporation Common Stoc - Yahoo Finance
CEL-SCI Corporation (CVM)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.10 - 0.11|
|52 Week Range||0.06 - 0.66|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.14|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|